SCHEMBL24837401

SCHEMBL24837401

CC(C)c1ccc(S(=N)(=O)C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ BCHE P06276 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ KAT6A Q92794 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ MCOLN3 Q8TDD5 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ PKM P14618 1/20 0.39
▸ PTPN5 P54829 1/20 0.38
▸ HSD11B1 P28845 1/20 0.36
▸ TYR P14679 1/20 0.36
▸ EPAS1 Q99814 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10180160 0.80 KIF11 (0.47) LMNAALDH1A1MAPTKDM4EGAA
SCHEMBL13364187 0.78 GAA (0.50) LMNAALDH1A1GAABCHEACHE
SCHEMBL24837458 0.77 FFAR4 (0.44) KAT6ACA12CA1CA2CA9
SCHEMBL2281688 0.75 ALDH1A1 (0.48) LMNAALDH1A1MAPTKDM4EGAA
SCHEMBL2326357 0.75 ALDH1A1 (0.44) ALDH1A1CA1CA2PKMHSD11B1
SCHEMBL29217885 0.75 LMNA (0.50) LMNAALDH1A1MAPTKDM4EGAA
SCHEMBL11951637 0.74 ALDH1A1 (0.44) LMNAALDH1A1MAPTKDM4EGAA
SCHEMBL15573782 0.74 CA2 (0.46) CA12CA1CA2CA9EPAS1
SCHEMBL12005156 0.73 ALDH1A1 (0.43) LMNAALDH1A1MAPTKDM4EGAA
SCHEMBL24010109 0.73 PKM (0.55) ALDH1A1KDM4EGAACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 ENPP1, ENPP3, SMPD1 LMNA 4127/4885ALDH1A1 1567/4885MAPT 4755/4885
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 ENPP1, ENPP3, SMPD1 LMNA 4127/4885ALDH1A1 1567/4885MAPT 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback